Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
CRBP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.92 - $61.90
Previous CloseN/A
Volume39.58K
Average Volume (3M)224.72K
Market Cap
$64.95M
Enterprise Value-$2.39M
Total Cash (Recent Filing)$303.02K
Total Debt (Recent Filing)$638.08K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
May 13, 2025EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.66
Shares Outstanding12,232,228
10 Day Avg. Volume256,641
30 Day Avg. Volume224,721
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$53.63Price Target Upside966.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Corbus Pharmaceuticals News
PremiumCompany Announcements
Corbus Pharmaceuticals Announces Board Member Departure
PremiumCompany Announcements
Corbus Pharmaceuticals Appoints Ian Hodgson as COO
PremiumCompany Announcements
Corbus Pharmaceuticals Advances in Oncology and ObesityPremiumCompany Announcements
Corbus Pharmaceuticals Reports Q4 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentCorbus Pharmaceuticals announced that the first subject has been dosed in the Phase 1 trial evaluating CRB-913, a CB1R inverse agonist for the treatment of obesity.
Financial PerformanceCorbus reported a net loss that was better than both the analyst's and consensus estimates, driven primarily by lower-than-expected R&D and SG&A expenses.
Regulatory ApprovalThe FDA granted Fast Track designation for CRB-701 in relapsed or refractory metastatic cervical cancer.
Bears Say
Drug Development RisksThere were concerns around the neuropsych adverse event profile shared with the mechanism of action of CRB-913, which could impact its development.
Market SentimentThe short interest in Corbus Pharmaceuticals is 23.2% of the float, indicating a significant portion of the market is betting against the stock.
Safety ConcernsThere are concerns about neuropsychiatric adverse events associated with CB1R inverse agonists.
---
Ownership Overview
31.09% Insiders
8.20% Mutual Funds
0.07% Other Institutional Investors
49.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $4.92 and its highest was $61.90 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $64.95M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is May 13, 2025 which is in 41 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Mar 11, 2025. The company reported -$0.78 earnings per share for the quarter, beating the consensus estimate of -$1.265 by $0.485.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.22.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 12,232,228 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$0.78 in its last earnings report, beating expectations of -$1.265. Following the earnings report the stock price went up 1.325%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in CRBP
---
Corbus Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.63 (966.20% Upside)
$53.63 (966.20% Upside)
Blogger Sentiment
Bullish
CRBP Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 151.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $43.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.75%
12-Months-Change
Fundamentals
Return on Equity
-59.34%
Trailing 12-Months
Asset Growth
451.35%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
---
CRBP Stock 12 Month Forecast
Average Price Target
$53.63
▲(966.20% Upside)
Technical Analysis
Assertio Therapeutics
―
Adicet Bio
―
Exagen
―
Pyxis Oncology
―
Acrivon Therapeutics, Inc.
―
Best Analysts Covering CRBP
1 Year
1 Year Success Rate
1/12 ratings generated profit
1 Year Average Return
-34.29%
reiterated a buy rating 22 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -34.29% per trade.
---